Mexidol, 50 mg/ml 2 ml 10 pcs

Pharmacodynamics

Mexidol® has antihypoxic, membranoprotective, nootropic, anticonvulsant, anxiolytic effect, increases resistance to stress. The preparation increases resistance to the main damaging factors, to oxygen-dependent pathological states (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication by alcohol and antipsychotic drugs (neuroleptics)).

Mexidol® improves cerebral metabolism and blood supply of the brain, improves microcirculation and blood rheology, reduces platelet aggregation. It stabilizes membrane structures of blood cells (erythrocytes and platelets) in hemolysis. It has a hypolipidemic effect, reduces the level of total cholesterol and LDL. It reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

The mechanism of action of Mexidol® is due to its antihypoxant, antioxidant and membranoprotective actions. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid/protein ratio, reduces membrane viscosity and increases its fluidity. It modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which increases their ability to bind to ligands, helps maintain the structural and functional organization of biomembranes, neurotransport and improve synaptic transmission. Mexidol® increases dopamine content in the brain. Causes enhancement of compensatory activity of aerobic glycolysis and reduction of the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia with increase of ATP, creatine phosphate and activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Mexidol® normalizes metabolic processes in ischemic myocardium, reduces the zone of necrosis, restores and improves myocardial electrical activity and contractility as well as increases coronary blood flow in ischemic area and reduces consequences of reperfusion syndrome in acute coronary failure. Increases antianginal activity of nitropreparations.

Mexidol® promotes the preservation of retinal ganglion cells and optic nerve fibers at progressive neuropathy caused by chronic ischemia and hypoxia. It improves the functional activity of the retina and the optic nerve, increasing visual acuity.

Pharmacokinetics

Intake

When Mexidol® is administered in doses of 400-500 mg, the Cmax in plasma is 3.5-4.0 µg/mL and is reached within 0.45-0.5 h.

Distribution

The drug is detectable in plasma for 4 hours after IV/m administration. Average retention time of the drug in the body is 0.7-1.3 h.

Elimination

Extracted from the body with urine mainly in glucuron-conjugated form and in small amounts unchanged.

Indications

The drug Mexidol® is used in adults over 18 years of age:
for acute cerebrovascular accidents;
for traumatic brain injuries and consequences of traumatic brain injuries;
with dyscirculatory encephalopathy (a disorder of the brain caused by a circulatory disorder);
with chronic ischemia (circulatory disorders) of the brain;
with vegetative dystonia syndrome (a condition caused by disruption of the nerves that control the functions of internal organs);
for mild (moderate) cognitive disorders (decreased memory, attention and mental performance);
for anxiety disorders against the background of neurotic and neurosis-like conditions;
in case of acute myocardial infarction (from the first day) as part of complex therapy;
for primary open-angle glaucoma (increased intraocular pressure) of various stages, as part of complex therapy;
to eliminate the manifestations of withdrawal syndrome in alcoholism (a set of complaints that arise after an abrupt cessation of alcohol consumption) with a predominance of neurosis-like and vegetative-vascular disorders;
in case of acute intoxication (poisoning) with antipsychotic drugs (medicines for the treatment of psychiatric diseases); in acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Pharmacological effect

Mexidol® increases the body’s resistance to various damaging factors during shock, hypoxia (insufficient oxygen supply to tissues) and ischemia (insufficient blood supply to tissues), cerebrovascular accidents, alcohol poisoning and antipsychotic drugs (neuroleptics). Mexidol® is able to neutralize reactive oxygen species (free radicals) formed in these diseases, thereby reducing damage that could cause cell death in the body.
If there is no improvement or you feel worse, you should consult a doctor.

Special instructions

Before using Mexidol®, consult your doctor. Be sure to tell your doctor if you have bronchial asthma or hypersensitivity to sulfites, as severe hypersensitivity reactions and bronchospasm may develop in this case.

Children and teenagers

The use of the drug in children and adolescents under 18 years of age is not recommended due to the lack of data on effectiveness and safety.

Driving vehicles and working with machinery

During the period of taking the drug, caution should be exercised when performing work that requires rapid psychophysical reactions (driving vehicles, machinery, etc.).

Active ingredient

Ethylmethylhydroxypyridine succinate

Composition

Active ingredient: ethylmethylhydroxypyridine succinate

Pregnancy

If you are pregnant or breastfeeding, think you may be pregnant, or are planning a pregnancy, consult your doctor before using this medicine. Mexidol® is contraindicated during pregnancy and breastfeeding.

Contraindications

Do not use Mexidol®:
if you are allergic to ethylmethylhydroxypyridine succinate or any of the other ingredients of this medicine (listed in section 6 of the leaflet);
if you have acute liver dysfunction;
if you have acute kidney problems;
if you are pregnant or breastfeeding;
if you are under 18 years of age.

Side Effects

Like all medicines, Mexidol® can cause side effects, although not everyone gets them.

Serious adverse reactions may occur but are very rare (may occur in less than 1 in 10,000 people).
Call your doctor immediately if you experience any of the following side effects:
anaphylactic shock (a serious allergic reaction that may include a sharp decrease in blood pressure, pallor, cold extremities, loss of consciousness);
angioedema (a serious allergic reaction that may include difficulty breathing, swelling of the face, neck, lips, tongue, throat), urticaria (an allergic itchy rash).
Other possible adverse reactions that may occur when using the drug Mexidol®

Very rare (may affect less than 1 in 10,000 people):
drowsiness;
headache, dizziness;
decrease or increase in blood pressure;
dry cough, sore throat, chest discomfort, difficulty breathing;
dry mouth, nausea;
unpleasant odor, metallic taste in the mouth;
itching, rash, redness of the skin;
feeling of warmth.

Interaction

Tell your doctor if you are taking, have recently taken, or may start taking any other medications.
The drug Mexidol®, when used simultaneously with certain drugs that reduce anxiety (benzodiazepine anxiolytics), drugs used to treat epilepsy (anticonvulsants, for example, carbamazepine), for the treatment of Parkinson’s syndrome/disease (antiparkinsonian drugs, for example, levodopa), as well as for the treatment and relief of angina attacks (nitro drugs), increases the severity of their actions.

The drug Mexidol® reduces the toxic effects of ethyl alcohol.

Overdose

If you are given more Mexidol® than you should, you may experience drowsiness or insomnia. If such symptoms appear, stop using the drug and consult your doctor. If possible, show your doctor the package of Mexidol®.

If you have questions about the use of the drug, contact your doctor or nurse.

Storage conditions

Keep the drug out of the reach of children and so that the child cannot see it.

Store the drug in a place protected from light at a temperature not exceeding 25 °C.

Shelf life

Do not use the drug after the expiration date (shelf life) indicated on the package. The expiration date is the last day of the given month.

Manufacturer

ZiO-Zdorovye CJSC, Russia